Object. Opioid administration following major intracranial surgery is often limited by a presumed lack of need and a concern that opioids will adversely affect postoperative outcome and interfere with the neurological examina tion. Nevertheless, evidence is accumulating that these patients suffer moderate to severe postoperative pain and that this pain is often undertreated. The authors hypothesized that intravenous patientcontrolled analgesia (PCA) would safely and more effectively treat postoperative supratentorial craniotomy pain than conventional as needed (PRN) therapy.
H istorically, the pain associated with intracranial surgery has been undertreated because of a pre sumed lack of need and concern that the use of opioids may interfere with the neurological examination or lead to neurological deterioration. 27 Much of the infor mation concerning the quality, duration, and treatment of pain following craniotomy surgery is anecdotal. Opioids, the analgesics most often prescribed for moderate to se vere pain, may produce sedation and miosis and mask signs of intracranial catastrophe. 20 Furthermore, opioids, even when administered in therapeutic doses, may depress minute ventilation, leading to hypercapnia, increased in tracerebral blood volume, and potentially increased intra cranial pressure and cerebral edema. 4 Moreover, why ex pose a patient to these risks when there is a presumed lack of need? Decades of training and anecdote have reinforced a widely held belief that patients do not experience intense pain following intracranial surgery, a belief supported by the fact that surgery on the brain parenchyma per se is not painful. 8 On the other hand, a growing body of published stud Efficacy of intravenous patient-controlled analgesia after supratentorial intracranial surgery: a prospective randomized controlled trial ies have reported that pain following intracranial surgery is in fact common, often intense, and undertreated. 5, 6, 11, 27, 29 Failure to adequately treat pain in other postoperative con ditions is not only associated with poor patient satisfaction but worse functional outcomes. 1, 3, 17 Indeed, aggressive as sessment and treatment of pain for other conditions is now routine and the standard of care. One of the most common and safest methods of effectively treating pain in adults and children is intravenous PCA. 2, 12, 25, 31 However, this meth od of pain management has rarely been used following craniotomy. Although intravenous PCA has been used in several studies to compare different analgesics following craniotomy, the efficacy and safety of intravenous PCA has not been studied in comparison with conventional PRN therapy. We hypothesized that intravenous PCA would safe ly and more effectively treat the pain of supratentorial craniotomy surgery than PRN therapy.
Methods
After obtaining approval from the institutional review board, eligible patients presenting for elective supratento rial craniotomy were recruited on the day of surgery. Those eligible needed to be opioidnaive, nonpregnant, English speaking adults, and able to use an intravenous PCA de livery system. Exclusion criteria included a history of sub stance abuse, obstructive sleep apnea, and epilepsy.
After obtaining written informed consent, all pa tients underwent standardized general anesthesia. Anes thesia was induced using intravenous propofol (2-3 mg/ kg), fentanyl (2-5 μg/kg), and vecuronium (0.1 mg/kg) and maintained with isoflurane, nitrous oxide, oxygen, and fentanyl up to a maximum of 2 μg/kg/hr as need ed. All patients received a scalp block or infiltration of the surgical site with bupivacaine. At the conclusion of surgery, neuromuscular blockade was antagonized with neostigmine and glycopyrrolate, and patients were taken to the NCCU for recovery. In the NCCU, patients were neurologically assessed for new immediate postopera tive neurological deficits, the ability to communicate, and the ability to physically use a PCA button before they were permitted to continue with randomization. Patients with new deficits or those who had communication prob lems, who could not manipulate the PCA device, or had received naloxone in the operating room were excluded from continuing in the study.
Patients were randomized to receive either 25-50 μg intravenous fentanyl every 30 minutes PRN or intrave nous PCA 0.5 μg/kg fentanyl with a lock-out interval of 15 minutes and a maximum of 4 demand doses/hour. Ad ditionally each patient was given acetaminophen 650 mg rectally every 4 hours while they were unable to take oral medication, followed by 1 g acetaminophen orally every 6 hours thereafter.
While in the NCCU, study patients were routinely as sessed (hourly for the first 10 hours then every 2 hours until discharge from the intensive care unit) for the following outcome variables: changes in neurological status, pain scores, incidence of uncontrolled pain (defined as a pain score ≥ 5/10 for > 2 hours), incidence of respiratory depres sion requiring an opioid antagonist or institution of ventila tory support, the number of emergency postoperative CT or MR imaging studies obtained for evaluation of neuro logical changes, incidence of pruritus, and the incidence, duration, and intensity of nausea and vomiting. Vital signs were continuously measured. All data were entered into a Microsoft Access database by a research coordinator for analysis.
Statistical Methods
Our previous investigation in adult patients under going major intracranial surgery found that 69% of 187 patients treated with PRN fentanyl experienced moderate to severe pain (selfreport score ≥ 4 on a 10-point pain scale). For this study, we assumed that the use of intrave nous PCA would reduce by 50% the number of patients with moderate to severe pain when compared with con ventional PRN fentanyl therapy. Using a 2-sided alpha of 0.05, 32 patients per treatment group would give an 80% power to detect at least a 50% decrease in the percentage of patients with pain scores ≥ 4.
Frequency data were analyzed using the Fisher ex act test or loglinear analysis (when frequency tables were other than 2 × 2), ordinal data were analyzed using KruskalWallis ANOVA, and continuous data were ana lyzed using ANOVA and, where appropriate, techniques for longitudinal data analysis. Most outcome variables (pain, fentanyl use, respiratory rate, oxygen saturation, systolic blood pressure, heart rate, GCS score, and Ram say Sedation Scale score) were treated as continuous vari ables, whose average over the entire NCCU length of stay was analyzed using 1-way ANOVA. With the exception of the fentanyl data, the initial hour was not included in the analysis because, for these variables, there would have been no differences between the control and intervention groups. Furthermore, for these variables, longitudinal data analysis was also carried out using a general estimat ing equation approach whose results were also confirmed using a mixedmodel approach. Results obtained from longitudinal data analysis are reported only for the data displayed in the figures because the results were not ma terially different from results obtained using 1-way ANO VA. Ordinal data for nausea and vomiting and pruritus were reduced to simple frequency tables representing the presence of the symptom at any time during the study pe riod. These symptom scales were also summed for each patient over the entire study period and analyzed using KruskalWallis ANOVA, and the result was reported only if it was materially different from that obtained from the frequency data. Additional power analysis of safety data was performed using the binomial distribution to com pute confidence intervals as a function of study size. Data were analyzed with Statistica 6.0 (StatSoft, Inc.) and, for longitudinal data analysis, Stata 10 (StataCorp. LP). Prob ability values ≤ 0.05 were considered significant.
Results
Between March 2006 and December 2007, we iden tified 601 eligible patients of whom 79 were randomized to receive either PRN or intravenous PCA analgesia (Fig.  1) . Both groups were similar with respect to demographic variables, intraoperative variables, and pain levels on ad mission to the NCCU (Table 1 ). Data collection was ter minated prematurely for 6 patients, but not before the cri terion of ≥ 10 hours of data collection (Table 1) . Of these 6 patients, 2 were withdrawn from the study because of uncontrolled pain (both in the PRN group), 1 because of uncontrolled nausea and vomiting (intravenous PCA group), and 3 patients (1 in the PRN and 2 in the intrave nous PCA group) because of neurological deterioration unrelated to opioid administration.
There were no significant differences in pain scores at the time (Hour 0) of admission to the NCCU (p = 0.875) ( Table 1 and Fig. 2 ). Thereafter, longitudinal data analysis demonstrated significant differences between the 2 groups over the course of the study (p = 0.015) (Fig. 2) . Patients in the intravenous PCA group had lower pain scores than those in the PRN group (2.53 ± 1.96 vs 3.62 ± 2.11 [p = 0.039]) during the 16 hours after their admission to the NCCU (Table 1 and Fig. 2 ). Consistent with this, patients in the intravenous PCA group also received significantly more fentanyl than those in the PRN group (44.1 ± 34.5 vs 23.6 ± 23.7 μg/hour; Table 1 and Fig. 3 ). There were no differences between the 2 groups in sedation scores, GCS scores, respiratory rate, or oxygen saturation ( Table  2) . Although heart rate and blood pressure were lower in the intravenous PCA group than the PRN group, this dif The primary reasons for not considering a patient for inclusion in the study were the availability of participating anesthesiologists, intensivists, and nurse coordinators for the anticipated period of study, or that the case was not scheduled to start at the beginning of the day and would decrease the hours of data collection prior to discharge from the NCCU the next day. Reasons for excluding patients included prior opiate use (5 patients), neurocognitive deficits that would preclude PCA use (4 patients), and anticipated use of cardiopulmonary bypass during intracranial aneurysm clipping (1 patient). The primary reason for loss of patients during the operative phase of the study was a decline in neurological function that would make use of PCA impossible or undesirable (10 patients). The 3 protocol violations were all related to use of intraoperative systemic analgesics other than fentanyl. Other reasons for exclusion of patients at this point included an unappreciated inability to use the PCA device despite maintenance of preoperative neurological status (2 patients), and postoperative recognition that the patient had, in fact, been on a regimen of opioids preoperatively (1 patient). Once patients were receiving fentanyl analgesia in either the PCA or PRN group, all contributed data that met the criterion of ≥ 10 hours over which data could be collected. As detailed in Table 1 , several patients were subsequently removed from the study due to uncontrolled pain (2 patients), uncontrolled nausea and vomiting (1 patient), or neurological deterioration (3 patients [1 in the PRN group and 2 in the intravenous PCA group]). OR = operating room.
ference was significant only for blood pressure (Table 2) . Finally, there were no statistically significant differences in the number of unscheduled brain imaging studies per formed to evaluate patients for neurological deterioration. Of these who did suffer neurological deterioration or re quired unscheduled brain imaging, none of these were at tributable to opiate administration.
Although there was a trend toward more nausea and vomiting in the intravenous PCA group, this did not reach significance (Table 1 ). This adverse event was examined in further detail, and although there were no differences in the actual incidence of nausea and vomiting, when either did occur the overall intensity and duration was signifi cantly worse in the PCA group (summed scores over time: 
Discussion
This prospective, randomized controlled trial clearly demonstrated the superiority of intravenous PCA over con ventional PRN therapy in treating postcraniotomy pain, without major adverse events in either group. Although only a few studies have been performed evaluating PCA therapy in the management of postcraniotomy pain, 13, 15, 26, 28, 30 we believe that this is the first randomized controlled trial di rectly comparing standard intravenous PCA fentanyl with PRN therapy in this patient population. Furthermore, the use of intravenous PCA in this study neither altered the neurological examination nor increased the incidence of neurological deterioration. These results are not consistent with the widely held belief that opioid administration in general, and intravenous PCA therapy in particular, is un safe in this patient population.
The need for postoperative analgesia and the degree of pain associated with craniotomy surgery has been dis puted in the past. 8 Only recently has a sufficiently coher ent picture developed to reconsider the traditional teaching that this pain is minimal.
6,27,29 Building on several earlier studies, a large prospective study of pain following major intracranial surgery recently demonstrated some period of moderate to severe pain (≥ 4 on a 0-10 scale) in 69% of patients on the 1st postoperative day and in 48% of patients on the 2nd postoperative day. 11 In contrast to other studies, patient satisfaction varied significantly with the quality of pain relief. Demographic and clinical factors linked to in creased pain following intracranial surgery have included sex, 21 younger age, 21 surgical site, 21 surgical approach, 14, 24 and use of perioperative neural blockade. Pain intensity is also a significant factor in studies evaluating the quality of recovery from intracranial surgery.
16,23
Despite the great advances that have occurred over the past 2 decades in neurosurgery, neuroanesthesia, and neu rosurgical intensive care, analgesic therapy following in tracranial surgery has remained a therapeutic conundrum. 9 On one hand, there is a basic desire by all physicians to alleviate pain and, on the other, there is a fundamental requirement to do no harm. Opioids, the analgesics most often prescribed for moderate to severe pain, have had a limited role in the analgesic therapy of patients who have undergone major intracranial surgery because of a concern that opioid administration can adversely affect the post operative neurological examination and outcome. 27 This concern has a reasonable degree of face validity but has not previously been well examined to determine if it is le gitimate.
Perhaps not surprisingly, we found that intravenous PCA was superior to PRN opioid administration in terms of pain relief. In the traditional PRN approach, a patient must complain of pain and ask for pain relief. The re sponding nurse must respond to and assess the patient, then locate, prepare, and administer the ordered medica tion at a fixed dose and time interval. Dosing and time intervals are often inadequate because of prescriber's lack of familiarity with the pharmacology of opioids, fear of opioidinduced side effects, an underappreciation of pain, and an irrational fear of inducing drug addiction. 22 Thus, even in the best of circumstances, there is a lag time inherent in asking for and receiving analgesia. Patient controlled analgesia permits patients to treat their pain by direct activation of a device that administers predeter mined, intermittent aliquots of analgesics. In this study, we used intravenous administration of the relatively po tent and rapidly acting opioid fentanyl.
Individual analgesic needs are accomodated by the diverse dosing patterns and immediate response that the PCA device permits. Patients typically receive < 50% of the total allowable, and already inadequate, PRN pre scription. 7, 18, 19 In this study, we observed a more generous administration of PRN opioid than noted in other studies as well as our previous observational study. 11 Several fac tors may have contributed to this increased use of fenta nyl in the PRN group. This was an unblinded study, and the institutional investigational review board mandated in their approval process that the PRN treatment group receive effective analgesia at doses that were greater and more frequent than usually used in the NCCU. Further Fig. 2 . Graph showing the hourly pain scores (discrete 0-10 scale) presented as the mean ± standard error of the mean. There were no significant differences in pain scores obtained at Hour 0, the time of admission to the NCCU (p = 0.875). Thereafter, longitudinal data analysis demonstrates significant differences between the 2 groups over the course of the study period (p = 0.026), which was more apparent when initial pain was used as a covariant (p = 0.015). Longitudinal data analysis demonstrates significant differences between the 2 groups (p = 0.004), which were more apparent when initial pain was also considered (p = 0.001).
more, the bedside nurses were mandated by the proto col to frequently assess and treat pain, and this may have affected their behavior. The nurses may also have been aware of the results of our previous study showing a high level of ineffectively treated pain in these patients, lead ing to a Hawthorne effect. Despite the PRN dosing being more generous and frequent than in our previous study, we were still able to demonstrate significant improve ments in analgesia in the intravenous PCA arm.
A potential criticism of this study is that more fen tanyl was used in the PCA group because more opioids were available to that group. However, the converse ar gument can be made that the increased use of opioids, when given the opportunity, attests to the degree of pain suffered by the postcraniotomy patient population and the inferiority of the PRN approach. Assuming that pa tients received the maximum dose possible, the PRN arm would get 100 μg fentanyl/hour, and the PCA group could get as much as 200 μg/hour. Although the patients in the PCA arm used nearly twice as much fentanyl per hour as those in the PRN arm, both had average doses well below the maximum total hourly dose (44.1 vs 23.6 μg/ hour). This difference in maximum allowable opioid may explain the improved pain scores with PCA and suggests that how much opioid a patient receives is as important as the method of delivery. Patientcontrolled analgesia may optimize the delivery and the total dose to achieve more effective pain relief.
When discussing the safety of PCA, the distinction must be made between the complications arising from the PCA as a modality of delivering analgesics and problems resulting from the opioids used in treating pain. There are actually few complications with PCA as a modality, and most occur because of programming errors, use of concomitant continuous opioid infusion, or initiation of the demand dose by individuals other than the patient (PCA by proxy or surrogate PCA). In this study none of these delivery complications occurred. On the other hand, opioids have side effects regardless of the method of administration including sedation and miosis (which may mask signs of an intracranial event), ventilatory de pression (which may lead to hypercapnia and increased intracerebral blood volume), 4 pruritus, nausea, vomiting, constipation, and hypotension. In fact, the 2 most feared adverse consequences of intravenous PCA management of postcraniotomy pain (respiratory depression and ex cessive sedation) did not occur in this study. Thus, one of the most important findings of this study was our ability to improve analgesia by providing more opioids via the PCA pump safely. This is especially notable since the pa tients in the PCA arm used nearly twice as much fentanyl as their counterparts in the PRN arm.
This study also found no difference in other adverse outcomes including nausea and vomiting, uncontrolled nau sea and vomiting, pruritus, and uncontrolled pain. Indeed, only 2 patients in this study had uncontrolled pain and both were in the PRN group. The tendency toward greater inten sity and duration of nausea and vomiting, when it did occur in the PCA group, warrants attention, especially given that nausea and vomiting are commonly associated with intra cranial surgery. 10 The increased nausea and vomiting in the PCA group is likely to be due to the higher total doses of fentanyl received by this group and underscores the need for aggressive and effective regimens to control this opioid induced side effect. If similar doses had been available in the PRN arm, a similar intensity of nausea and vomiting may have been seen.
We recognize several other limitations in this study. As noted previously, the study was not blinded as to the drug administration groups. There was no obvious way to implement blinding since the bedside nurse is an ac tive participant in the PRN administration arm and the patient is an active participant in both arms. Given that the outcomes have rather clear and agreed on definitions, we believe that the bias introduced by lack of blinding was minimal. The possible exception to this would be the pain scores that are selfreported and hence carry addi tional measurement bias. Given the safety demonstrated in this study, future testing of postcraniotomy analgesic regimens in addition to or in conjunction with PCA may be implemented using blinding. Although we did not observe any respiratory events requiring naloxone administration or neurological events attributable to opiate administration, these data should be interpreted cautiously as the study was not powered with respect to safety. The observation of no events in the in tervention group that contained 29 patients has a 95% CI of 0-11.9%. If all 64 patients in the study are considered, the 95% CI becomes 0-5.6%. If major adverse events are, in fact, rare, demonstrating this in an appropriately pow ered study could be challenging. If a major adverse event rate of 1% is assumed, 100 patients would be required to achieve a 95% CI of 0-3%, 200 patients for it to be 0-2.5%, and 400 patients for it to be 0-2%. Therefore, a study much larger than the current one would be required to substantiate our findings supporting the safety of intra venous PCA.
Another possible criticism of this study is that we only studied patients undergoing supratentorial cranioto my. We did this because patients undergoing infratentori al surgery experience substantially more pain than those undergoing supratentorial craniotomy 11 and because of the concern that posterior fossa procedures may be more prone to adverse neurological events. Thus, our results may not extend to that population. We are currently con ducting a prospective randomized controlled trial to an swer this question. Finally, we acknowledge that this was a small study (< 70 patients) powered to detect differences in pain control. Larger studies designed to assess safety are warranted. Additionally, this was a singleinstitution study, and our hospital has a dedicated NCCU that is highly specialized in the care of neurosurgical and criti cal neurological patients and is staffed 24 hours a day by a group of neurointensivists as well as its specially edu cated critical care nurses. Therefore, our results may not be easily duplicated in other environments that are less specialized or in other neurosurgical populations.
Conclusions
Intravenous PCA with fentanyl provides superior pain relief compared to a conventional PRN dosing strategy for the management of supratentorial craniotomy pain and does not appear to increase the incidence of major adverse events. We encourage others to improve the quality of pain relief in this patient population by instituting intravenous PCA.
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